5[4]Grabc zewska Z,Bialoszynski T,Szymanski P,et al.The effect of trimetazidine added to maximal anti-sichemic therapy in patients with advanced coronary artery disease.Cardiol J,2008,15(4):344-350.
6Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trmetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl eoenzyme A thiolase [ J ]. Circ Res,2000 ; 86 ( 5 ) : 580-8.
7Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischemic heart disease:the pharmacology of trimetazidine[ J]. Fundam Clin Pharmacol,2006;17 (2) :155-45.
8Tabbi-Anneni I, Helies-Toussaint C, Morin D, et al. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover [ J ]. J Pharmacol Exp Ther, 2003 ; 304 ( 3 ) : 1003 -9.
9EI-Kady T, EI-Sabban K, Gabaly M, et al. Effects of trimetazidine on myocardial perfusion and the contractile response of chroniccally dysfunctional myocardium in ischemic cardiomyophy : a 24-month study [ J ]. Am J Cardiovasc Drugs,2005 ;5(4) :271-8.
10Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazi- dine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by in hibiting mitochondrial long chain3-ketoacyl coenzyme A thiolase [ J ]. Circ Res,2008,86 ( 5 ) :580 - 588.
